Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2009 1
2010 2
2011 4
2012 3
2013 2
2014 3
2015 4
2016 6
2017 9
2018 10
2019 6
2020 4
2021 6
2022 12
2023 15
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: todaka a. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M, Nakachi K, Kobayashi S, Ohba A, Imaoka H, Terashima T, Ishii H, Mizusawa J, Katayama H, Kataoka T, Okusaka T, Ikeda M, Sasahira N, Miwa H, Mizukoshi E, Okano N, Mizuno N, Yamamoto T, Komatsu Y, Todaka A, Kamata K, Furukawa M, Fujimori N, Katanuma A, Takayama Y, Tsumura H, Fukuda H, Ueno M, Furuse J; Hepatobiliary and Pancreatic Oncology Group of Japan Clinical Oncology Group (JCOG). Ozaka M, et al. Among authors: todaka a. Eur J Cancer. 2023 Mar;181:135-144. doi: 10.1016/j.ejca.2022.12.014. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36652891 Free article. Clinical Trial.
Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.
Imaoka H, Ikeda M, Umemoto K, Sunakawa Y, Ueno M, Ueno H, Ozaka M, Kuwahara T, Okano N, Kanai M, Hisano T, Suzuki Y, Asagi A, Shioji K, Todaka A, Tsuji K, Ikezawa K, Miki I, Komatsu Y, Akutsu N, Yamashita T, Okuyama H, Furuse J, Nagano H. Imaoka H, et al. Among authors: todaka a. Jpn J Clin Oncol. 2023 Aug 30;53(9):764-773. doi: 10.1093/jjco/hyad062. Jpn J Clin Oncol. 2023. PMID: 37325968 Free PMC article. Review.
Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106.
Mizuno N, Ioka T, Ogawa G, Nakamura S, Hiraoka N, Ito Y, Katayama H, Takada R, Kobayashi S, Ikeda M, Miwa H, Okano N, Kuramochi H, Sekimoto M, Okusaka T, Ozaka M, Todaka A, Gotoh K, Tobimatsu K, Yamaguchi H, Nakagohri T, Kajiura S, Sudo K, Okamura K, Shimizu S, Shirakawa H, Kato N, Sano K, Iwai T, Fujimori N, Ueno M, Ishii H, Furuse J; Hepatobiliary and Pancreatic Oncology Group (HBPOG) of Japan Clinical Oncology Group (JCOG). Mizuno N, et al. Among authors: todaka a. Jpn J Clin Oncol. 2023 Jul 31;53(8):704-713. doi: 10.1093/jjco/hyad044. Jpn J Clin Oncol. 2023. PMID: 37248668 Free PMC article. Clinical Trial.
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Taniguchi H, Yamazaki K, Masuishi T, Kawakami T, Onozawa Y, Honda K, Kadowaki S, Narita Y, Tsushima T, Hamauchi S, Todaka A, Yokota T, Ando M, Mori K, Shirasu H, Yasui H, Muro K. Taniguchi H, et al. Among authors: todaka a. Oncologist. 2023 Nov 2;28(11):e1108-e1113. doi: 10.1093/oncolo/oyad143. Oncologist. 2023. PMID: 37284901 Free PMC article. Clinical Trial.
Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma.
Sugiura T, Uesaka K, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Asakura H, Todaka A, Fukutomi A. Sugiura T, et al. Among authors: todaka a. Ann Gastroenterol Surg. 2020 May 15;4(4):455-463. doi: 10.1002/ags3.12345. eCollection 2020 Jul. Ann Gastroenterol Surg. 2020. PMID: 32724890 Free PMC article.
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Yamamoto N, Koyama T, Shimizu T, Todaka A, Kawakami T, Erzen D, Sarashina A, Li B, Hou J, Yamazaki K. Yamamoto N, et al. Among authors: todaka a. Cancer Chemother Pharmacol. 2023 Jun;91(6):469-480. doi: 10.1007/s00280-023-04527-6. Epub 2023 May 4. Cancer Chemother Pharmacol. 2023. PMID: 37140602 Clinical Trial.
Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K. Matsubayashi H, et al. Among authors: todaka a. J Hum Genet. 2023 Feb;68(2):81-86. doi: 10.1038/s10038-022-01097-y. Epub 2022 Dec 8. J Hum Genet. 2023. PMID: 36482120
78 results